TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01555151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Description: Mometasone furoate (MF) 80 µg once daily delivered via Concept1 device; MF 200 μg once daily delivered via Concept1 device; MF 320μg once daily delivered via Twisthaler® device or 800 μg once daily delivered via Twisthaler® device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Description: Mometasone furoate (MF) 80 µg once daily delivered via Concept1 device; MF 200 μg once daily delivered via Concept1 device; MF 320μg once daily delivered via Twisthaler® device or 800 μg once daily delivered via Twisthaler® device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Description: Mometasone furoate (MF) 80 µg once daily delivered via Concept1 device; MF 200 μg once daily delivered via Concept1 device; MF 320μg once daily delivered via Twisthaler® device or 800 μg once daily delivered via Twisthaler® device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Description: Mometasone furoate (MF) 80 µg once daily delivered via Concept1 device; MF 200 μg once daily delivered via Concept1 device; MF 320μg once daily delivered via Twisthaler® device or 800 μg once daily delivered via Twisthaler® device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Concept 1
Description: A single dose dry powder inhaler (SDDPI)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Concept 1
Description: A single dose dry powder inhaler (SDDPI)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Twisthaler
Description: A single dose dry powder inhaler (SDDPI)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Twisthaler
Description: A single dose dry powder inhaler (SDDPI)
Study: NCT02493504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: 100units/kg of heparin were administered for the case group after dissection prior to anastomosis.
Study: NCT03520478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3680
Description: Tablet. Specifications of 80 mg; orally, once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide
Description: Tablet. Specifications of 50 mg; orally, once a day
Study: NCT01017588

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PSU lumbar back support
Description: wear PSU back supprt during doing rubber tapper
Study: NCT03130179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorette Strongmint lozenge 4 mg
Description: A single dose of one Nicorette lozenge 4mg lozenge administrated orally to slowly dissolve in the mouth.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niquitin MiniMint lozenge 4 mg
Description: A single dose of one Niquitin Minimint lozenge 4mg administrated orally to slowly dissolve in the mouth.
Study: NCT02015325

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Planet Water Foundation's Program
Description: Planet Water Foundation's Program (PWP) provides a school-based program with an aim to improve health outcomes in children using three components: (a) access to safe water, (b) access to hand washing facilities, and (c) access to water-health and hygiene education. As part of the PWP, access to safe water is provided through the use of an AquaTower, which incorporates an Ultra Filtration (UF) system. WASH messaging is also posted around the AquaTower as derived from PWP's school-based four week Water-Health \& Hygiene education program.
Study: NCT03382015

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BKR-013 or Placebo
Description: Encapsulated L-glutamine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: BKR-013 or Placebo
Description: Encapsulated L-glutamine
Study: NCT01366261

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: semirigid thoracoscopy
Description: thoracoscopy with semirigid instrument

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rigid thoracoscopy
Description: thoracoscopy with rigid instrument
Study: NCT04537546

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OBESINOV elasto-compressive belt
Description: It is a customised medical device, using a technique for calculating the compression ratio adapted to each patient according to his morphology
Study: NCT01486641

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterolateral approach
Description: Anterolateral approach acording to Gammer for hip arthroplasty.
Study: NCT01507467

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Accl. RT
Description: Accelerated Radiotherapy: Radiotherapy 66-70 Gy, 2Gy/fx, 6fx/week

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accl. RT
Description: Accelerated Radiotherapy: Radiotherapy 66-70 Gy, 2Gy/fx, 6fx/week

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accl. radiotherapy + Nimorazole
Description: Radiation: Radiotherapy 66-70 Gy, 2Gy/fx, 6fx/week plus Nimorazole (tablets or powder) 1.2 g/m2 body surface in connection with the first daily radiation treatments
Study: NCT03677050

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smart phone patient education application
Description: Smart phone patient education application including a personalized colonoscopy preparation scheme and information about the procedure.
Study: NCT01886313

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Civamide Nasal Spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02594423

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fine Needle Diathermy
Description: Fine needle diathermy is a surgical procedure that is used in the treatment of corneal NV. It is a safe and effective method for corneal vessels occlusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab is a humanized monoclonal antibody that binds to isoforms of VEGF-A .
Study: NCT00864890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram HBr 40 mg tablets, single dose
Description: A: Experimental Subjects received Purepac formulated products under fed conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CelexaTM 40 mg tablets, single dose
Description: B: Active comparator Subjects received Forest Labs formulated products under fed conditions
Study: NCT03623594

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical repair of the diastasis
Description: Repair of the diastasis with a double row plication using absorbable Quill suture
Study: NCT01657474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weekly application of EpiFix plus standard of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biweekly application of EpiFix plus standard of care
Study: NCT02147366

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music & lifestyle changes
Description: Music intervention involved listening to raga bhimpalas played on bansuri/flute (an Indian instrument) for 15 minutes daily for 3 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle
Description: Lifestyle intervention was based on Joint national committee VII guidelines for hypertension
Study: NCT02432222

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Arts Training
Description: Visual arts training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Training
Description: Music training
Study: NCT00896779

Intervention type: DRUG
Group type: OTHER
Intervention: ranibizumab
Description: Group 1 - 0.5mg intravitreal injection every month for 3 months then as needed for 12 months~Group 2 -0.5mg intravitreal injection every month for 6 months then as needed for 12 months

Intervention type: DRUG
Group type: OTHER
Intervention: ranibizumab
Description: Group 1 - 0.5mg intravitreal injection every month for 3 months then as needed for 12 months~Group 2 -0.5mg intravitreal injection every month for 6 months then as needed for 12 months
Study: NCT00152282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil/Premarin
Description: Asoprisnil 5mg and Premarin 0.625 mg Tablets, oral Daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil/Premarin
Description: Asoprisnil 10mg and Premarin 0.625 mg Tablets, oral Daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil/Premarin
Description: Asoprisnil 25mg and Premarin 0.625 mg Tablets, oral Daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and Premarin
Description: Placebo and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
Study: NCT04366050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril 2.5 MG Oral Capsule
Description: Include description or ramipril from protocol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo
Study: NCT01516840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: 10 mg twice daily for 21 days, followed by 15 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: 15 mg twice daily for 21 days, followed by 15 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin
Description: To be adjusted to maintain the activated partial thromboplastin time (aPTT) prolongation (1.5 to 2.5 times the control)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: To be adjusted on the basis of prothrombin time-international normalized ratio (PT-INR) values target range (1.5 to 2.5)
Study: NCT04429854

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma
Description: 4 units of convalescent plasma:~* 2 units of plasma are administered within 12h after randomization, but preferably as soon as practically possible~* 2 units of plasma should be administered between 24h and 36h after the first infusion~Other investigational products may be added as part of the adaptive study design.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Since there are no current approved treatment options for COVID-19, the standard of care is mostly supportive.

Intervention type: DRUG
Group type: OTHER
Intervention: Standard of care
Description: Since there are no current approved treatment options for COVID-19, the standard of care is mostly supportive.
Study: NCT03840512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD
Description: CBD + Standard aGVHD prophylaxis calcineurin inhibitor (cyclosporine or tacrolimus) + methotrexate (MTX).~Subjects transplanted from unrelated donors or from mismatched siblings will also receive anti-T cell globulin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD
Description: CBD + Standard aGVHD prophylaxis calcineurin inhibitor (cyclosporine or tacrolimus) + methotrexate (MTX).~Subjects transplanted from unrelated donors or from mismatched siblings will also receive anti-T cell globulin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD
Description: CBD + Standard aGVHD prophylaxis calcineurin inhibitor (cyclosporine or tacrolimus) + methotrexate (MTX).~Subjects transplanted from unrelated donors or from mismatched siblings will also receive anti-T cell globulin.
Study: NCT02831192

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: microtransplantation
Description: HLA mismatched donor mobilized prepheral stem cell infusion
Study: NCT04143399

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: holmium laser enucleation of the prostate
Description: cystoscopic transurethral enucleation of the prostate using Holmium laser (Versa pulse 100W; Lumenis; Germany)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar resection of the prostate
Description: cystoscopic transurethral resection of the prostate using bipolar energy
Study: NCT03366675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2811
Description: AZD2811 100mg/vial
Study: NCT03078075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone: Vivitrol®
Description: Naltrexone: 380 mg vial, 4 intramuscular injections administered every 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PLB) Injectable
Description: Placebo: 4 intramuscular injections administered every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion: Wellbutrin XL®
Description: Bupropion: 450 mg oral dose daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PLB) Oral
Description: Placebo: once-daily oral placebo tablets
Study: NCT00890149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron (4ug/kg bid),

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo bid

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BASICS Plus
Description: Brief Alcohol Screening and Intervention for College Students. Brief behavioral intervention to reduce drinking.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: BASICS Plus
Description: Brief Alcohol Screening and Intervention for College Students. Brief behavioral intervention to reduce drinking.
Study: NCT03360097

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Frozen Embryo Transfer
Description: Patient's embryos are cultured to day 6, vitrified and transferred in a cryo-synthetic cycle
Study: NCT02114268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI8897 Intravenous
Description: Participants received a single fixed dose of 300 mg MEDI8897 intravenous infusion on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received placebo on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI8897 Intravenous
Description: Participants received a single fixed dose of 1000 mg MEDI8897 intravenous infusion on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI8897 Intravenous
Description: Participants received a single fixed dose of 3000 mg MEDI8897 intravenous infusion on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI8897 Intramuscular
Description: Participants received a single fixed dose of 100 mg MEDI8897 intramuscular injection on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI8897 Intramuscular
Description: Participants received a single fixed dose of 300 mg MEDI8897 intramuscular injection on Day 1.
Study: NCT02261779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranylcypromine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tretinoin
Study: NCT00627302

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-400
Description: Day of Surgery: Starting 2 hours after surgery Instill one drop in randomized eye every two hours. Day 1-Week 1: Instill one drop in randomized eye four times daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systane
Description: Day of Surgery: Starting 2 hours after surgery Instill one drop in randomized eye every two hours. Day 1-Week 1: Instill one drop in randomized eye four times daily
Study: NCT03483467

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Omnigen
Description: For those randomised onto the investigational arm, a dual layer of the Omnigen product will be applied at baseline and at every fortnightly trial visit until healing or the end of the 12 week period whichever occurs first, according to the standard study procedure.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dummy Packaging
Description: For those randomised into the control arm, dummy packaging will be opened at the time of application of standard of care, to ensure the same experience is received to those on the experiential arm.
Study: NCT02049268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine + Alcohol
Description: 14 mg nicotine patch applied in combination with vodka and orange juice alcoholic beverage (to reach blood alcohol level (BAL) = 0.08 based on subject weight, which is approximately 2-3 drinks for 400 mL volume)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Nicotine + Alcohol
Description: Placebo nicotine patch applied in combination with vodka and orange juice alcoholic beverage (to reach BAL = 0.08 based on subject weight, which is approximately 2-3 drinks for 400 mL volume)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine + Placebo Alcohol
Description: 14 mg nicotine patch applied in combination with 400 mL orange juice beverage with a trace of alcohol to create placebo alcohol mixture.
Study: NCT01118416

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV prevention intervention randomized control trial
Description: Substance using HIV-negative young MSM who engage in sexual risk are randomized to either a motivational interviewing or an education condition to reduce sexual risk and drug use.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV prevention intervention randomized control trial
Description: Substance using HIV-negative young MSM who engage in sexual risk are randomized to either a motivational interviewing or an education condition to reduce sexual risk and drug use.
Study: NCT04340557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Standard of care plus the starting dose of losartan 12.5mg (investigator has option to increase dose on days 2-10 based on tolerance of SBP) of losartan taken twice daily for up to 10 days. Upon the treating clinician's discretion, losartan may be continued beyond 10 days for non-COVID-19 indications.
Study: NCT02671045

Intervention type: GENETIC
Intervention: Genomic profile by FoundationOne
Description: Proprietary comprehensive genomic profile.

Intervention type: GENETIC
Intervention: Genomic profile by FoundationOne
Description: Proprietary comprehensive genomic profile.

Intervention type: GENETIC
Intervention: Genomic profile by FoundationOne
Description: Proprietary comprehensive genomic profile.

Intervention type: GENETIC
Intervention: Genomic profile by other methods
Description: Genomic profiling by other testing methods.

Intervention type: GENETIC
Intervention: Genomic profile by other methods
Description: Genomic profiling by other testing methods.

Intervention type: GENETIC
Intervention: Genomic profile by other methods
Description: Genomic profiling by other testing methods.
Study: NCT03342313

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food - Sandwich
Description: Sandwich as a breakfast for testing chewing activities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food - Sandwich
Description: Sandwich as a breakfast for testing chewing activities.
Study: NCT00951301

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mangosteen juice
Description: 6 ounces of juice containing mangosteen taken twice daily, AM and PM, for 6 months duration of study participation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo juice
Description: 6 ounces of specially prepared juice not containing mangosteen taken twice daily, AM and PM, for 6 months duration of the study participation.
Study: NCT01309139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Medium dose of oral inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Medium dose of oral inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 54903
Description: Medium dose of oral inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 54903
Description: Medium dose of oral inhalation
Study: NCT00505596

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informed free choice
Description: Women will be instructed to view an updated prenatal testing decision aid and will be told that they can have whatever tests they would like (including no tests) and that tests that are not covered by their insurance will be paid for by the study
Study: NCT03200054

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adherence Clubs
Description: Women will be referred to the ACs at their postpartum ART clinic visit at the midwife obstetric unit (MOU) at the Gugulethu community health centre (CHC). AC visits occur 2-4 monthly at a community hall near the CHC. At routine visits, which last \~1 hour, community health workers provide health education, weigh participants, ask about symptoms, and dispense pre-packed ART. Symptomatic participants are referred back to the main ART facility at the CHC for assessment by a nurse. A nurse performs routine phlebotomy at an annual club visit, and does a clinical assessment and reviews blood results at the subsequent visit. Participants requiring more regular follow-up and those with raised viral loads are referred back to the ART clinic at the CHC by the nurse.
Study: NCT01054950

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Our food allergy nurse will contact our intervention group and discuss any questions or concerns they may have regarding their child's food allergy.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo phone call
Description: Phone call w/ no behavioral counseling
Study: NCT00515957

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: genetically modified CTLs in combo with CD45 antibodies
Description: LMP1- and LMP2- specific cytotoxic T-lymphocytes (CTL) in combination with CD45 monoclonal antibody (MAb).~--Infusions of CD45 MAbs: A fixed dose of CD45 MAbs will be used determined from our previous and ongoing studies in stem cell transplant recipients will be used43, 400ug/kg over 6 to 8 hrs daily x 4 given as 4 daily intravenous infusions that will be completed 48-72 hours prior to CTL infusion.~Day 1 YTH 24/54 400ug/kg over 6 to 8 hr 2 YTH 24/54 400ug/kg over 6 to 8 hr 3 YTH 24/54 400ug/kg over 6 to 8 hr 4 YTH 24/54 400ug/kg over 6 to 8 hr 5 Rest 6-8 CTL Infusion (provided CD45 MAb level \<100 ng/ml)~--LMP1- and LMP2-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.~2x 10\^7 cells/m2~1x 10\^8 cells/m2 3 x 10\^8 cells/m2~1 x 10\^9 cells/m2
Study: NCT01431274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium + olodaterol
Description: fixed dose combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium
Description: low dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olodaterol
Description: one dose only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium
Description: high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium + olodaterol
Description: fixed dose combination

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respimat
Description: Respimat inhaler

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respimat
Description: Respimat inhaler

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respimat
Description: Respimat inhaler

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat
Description: Respimat inhaler

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat
Description: Respimat inhaler